HERTHENA-Breast04 THERAPEUTIC TRIAL EVALUATING PATRITUMAB DERUXTECAN IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER Die HERTHENA-Breast04-Studie ist noch nicht in Deutschland gestartet, der Start wird aber in den kommenden...

NOGGO S18 – EMRISK DEVELOPMENT OF A RISK PREDICTION MODEL FOR NAUSEA AND VOMITING DURING CHEMOTHERAPY What is being investigated in this study? The EMRISK study is a two-phase observational...

EvoPAR-Breast01 Study STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY WITH SARUPARIB AND CAMIZESTRANT IN THE TREATMENT OF PATIENTS WITH HER2-NEGATIVE, ER-POSITIVE, ADVANCED BREAST CANCER Die EvoPAR-Breast01...

CAPItello-292 Study THERAPY STUDY TO EVALUATE A NEW COMBINATION THERAPY WITH CAPIVASERTIB, FULVESTRANT AND A CDK4/6 INHIBITOR IN PATIENTS WITH HER2-NEGATIVE, HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER Die CAPItello-292 ist eine...

CAMBRIA-2 Study THERAPEUTIC STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT IN THE TREATMENT OF PATIENTS WITH ER-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER Die CAMBRIA-2 ist eine offene (behandelnde Ärzt:innen...

CAMBRIA-1 Study THERAPY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT IN THE TREATMENT OF PATIENTS WITH ER-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER Die CAMBRIA-1 ist eine offene (behandelnde Ärzt:innen...

EPIK-B5 Study This study can enroll adult men and postmenopausal women with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation Breast cancer has various classifications, including by stage or...

EMBER-4 Study Endocrine therapy with Imlunestrant in high-risk patients with early ER-positive and HER2-negative breast cancer and completed endocrine therapy EMBER-4 is a randomized, unblinded (patients and physicians know the...

TROPION-Breast04 Study Therapy with antibody-drug conjugate and immunotherapy or standard therapy in previously untreated patients with early-stage triple-negative breast cancer TROPION-Breast04 is a randomized (treatment assignment for the specific patient...

MINERVA Study Combination therapy with Abemaciclib and endocrine therapy in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer with a focus on digital side effect management https://youtu.be/MRxnbZA1Kn8...

SURVIVE Study Breast cancer aftercare study for women and men with early-stage breast cancer, comparing standard aftercare with intensified aftercare https://www.youtube.com/watch?v=5EhOeRa2CJo&ab_channel=ForumGynOnkologie What is being investigated in this study? The SURVIVE...

ADAPTlate Study Personalized therapy study in patients with hormone receptor-positive, HER2 receptor-negative early-stage breast cancer who have a clinically or genomically high risk of late recurrence The ADAPTlate is a...

PROVIDENCE Study A non-interventional study to collect clinical and quality of life data in patients with HER2+ or HER2-low inoperable or metastatic breast cancer who receive trastuzumab deruxtecan as second-line...

GeparPiPPa / GBG-105 THERAPY STUDY TO EVALUATE THE POTENTIAL ADDITIONAL EFFICACY AND SAFETY OF INAVOLISIB IN THE PRE-OPERATIVE TREATMENT OF PATIENTS WITH HER2-POSITIVE, HR-POSITIVE, PIK3CA-MUTATED EARLY BREAST CANCER. GeparPiPPa is...

PROOFS – Registry Study A REGISTRY STUDY FOR LONG-TERM FOLLOW-UP OF PATIENTS WITH EARLY-STAGE LUMINAL BREAST CANCER WHO ARE TREATED WITH ENDOCRINE THERAPY PLUS OVARIAN FUNCTION SUPPRESSION (OFS) OR STANDARD...